Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Japan Tobacco Inc Announces Elvitegravir (JTK-303) Receives EU regulatory Approval


Tuesday, 19 Nov 2013 01:00am EST 

Japan Tobacco Inc announced that a novel HIV integrase inhibitor, the Company's original compound elvitegravir (JTK-303), has been approved by the European Medicines Agency (EMA). The drug is to be marketed as Vitekta in the European Union. Japan Tobacco Inc. The Company announced that a statement has been issued to this effect by Gilead Sciences, Inc. (Gilead) of Foster City, California, to which the Company licensed elvitegravir in March 2005 with exclusive rights to develop and commercialize the drug worldwide, excluding Japan. 

Company Quote

3373.0
-60.5 -1.76%
26 Dec 2014